Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00510354
Status:
COMPLETED
Last Update Posted:
2020-09-10
First Post:
2007-07-31
Brief Title:
Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors GIST and Are Resistant to Imatinib Mesylate
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Organization Data
Organization:
Novartis
Class:
INDUSTRY
Study ID:
CRAD001C2454
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Novartis Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None